Inari Medical

66 articles with Inari Medical

• Inari Medical Reports First Quarter 2022 Financial Results

  5/4/2022

  Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its first quarter ended March 31, 2022.

• Inari Medical to Present at the Bank of America 2022 Healthcare Conference

  4/28/2022

  Inari Medical, Inc. announced that its management team will present at the Bank of America 2022 Healthcare Conference on Thursday, May 12, 2022 at 10:40 a.m. Pacific Time at the Encore Hotel in Las Vegas.

• Inari Medical to Announce First Quarter 2022 Financial Results

  4/20/2022

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced today that it will release its first quarter 2022 financial results on Wednesday, May 4, 2022.

• Inari Medical Announces Closing of Underwriters’ Over-Allotment Option in Connection with Offering of Common Stock

  3/21/2022

  Inari Medical, Inc. announced that it has completed the sale of an additional 300,000 shares of its common stock, pursuant to the exercise in full of the over-allotment option granted to the underwriters in connection with Inari’s recently completed underwritten public offering of 2,000,000 shares of common stock, at the public offering price of $81.00 per share, less underwriting discounts and commissions.

• Inari Medical Announces Pricing of Offering of Common Stock - Mar 11, 2022

  3/11/2022

  Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the pricing of an underwritten public offering of 2,000,000 shares of its common stock at a public offering price of $81.00 per share, before underwriting discounts and commissions.

• Inari Medical Announces Proposed Offering of Common Stock

  3/10/2022

  Inari Medical, Inc. today announced the commencement of an underwritten public offering of 2,000,000 shares of its common stock.

• Inari Medical Appoints Robert Warner to Board of Directors

  3/1/2022

  Inari Medical, Inc. a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, announced the appointment of Mr. Robert Warner to its board of directors.

• Inari Medical Reports Fourth Quarter and Full Year 2021 Financial Results

  2/23/2022

  Inari Medical, Inc., a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, reported financial results for its fourth quarter and full year ended December 31, 2021.

• Inari Medical Announces First Patient Enrolled in the PEERLESS Trial, a Randomized Controlled Trial Evaluating Outcomes of the FlowTriever® System in Pulmonary Embolism Patients

  2/15/2022

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) today announced that the first patient has been enrolled in PEERLESS, a prospective, randomized controlled trial (“RCT”) comparing the outcomes of patients with intermediate-high risk pulmonary embolism (“PE”) treated with the FlowTriever system versus catheter-directed thrombolysis (“CDT”).

• Inari Medical to Announce Fourth Quarter and Full-Year 2021 Financial Results

  2/10/2022

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that it will release its fourth quarter and full-year financial results on Wednesday, February 23, 2022.

• Inari Medical to Present at Upcoming Investor Conferences - Feb 01, 2022

  2/1/2022

  Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced that its management team will present at the following investor conferences.

• Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue

  1/10/2022

  Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported preliminary unaudited fourth quarter 2021 revenue.

• Inari Medical to Present at the 40th Annual J.P. Morgan Healthcare Conference

  12/29/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 40th Annual J.P. Morgan Healthcare Conference.

• Inari Medical Reports Third Quarter 2021 Financial Results

  11/9/2021

  Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, reported financial results for its third quarter ended September 30, 2021.

• 

  Clinical Catch-Up: October 25-29

  11/1/2021

  Yet another busy week for clinical trial news. Here’s a look.

• Inari Medical Announces 6-month FLASH Registry Interim Data Demonstrating Benefits of Lytic-Free Mechanical Thrombectomy in 500 Real-World PE Patients

  10/28/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced positive acute and long-term interim results from the first 500 pulmonary embolism (“PE”) patients enrolled in the FlowTriever Outcomes Registry (“FLASH”).

• Inari Medical to Announce Third Quarter 2021 Financial Results

  10/26/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today it will release its third quarter financial results on Tuesday, November 9, 2021.

• 

  Clinical Catch-Up: October 18-22

  10/25/2021

  It was yet another busy week for clinical trial news. Here’s a look.

• Inari Medical Announces Randomized Controlled Trial Evaluating Clinical Outcomes of the FlowTriever® System in Pulmonary Embolism Patients

  10/18/2021

  Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced planned enrollment of the PEERLESS trial.

• Inari Medical Appoints Dana G. Mead, Jr. to Board of Directors

  10/1/2021

  Inari Medical, Inc., a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced the appointment of Mr. Dana G. Mead, Jr. to its board of directors.